30 Day Trial

NuVasive Reports 3Q16 Revenue

Share:

NuVasive reported 3Q16 revenue of US $239.6MM, +19.5% from 3Q15. (U.S. $208.3MM, +18.1%; ex-U.S. $31.4MM, +29.8%

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.